STOP-SST: Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT05149495

Collaborator

(none)

100

Enrollment

Location

17.6

Anticipated Duration (Months)

5.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described.

Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.

Condition or Disease	Intervention/Treatment	Phase
Acromegaly

Study Design

Study Type:

Observational

Anticipated Enrollment :

100 participants

Observational Model:

Case-Only

Time Perspective:

Retrospective

Official Title:

Maintenance of Remission After Discontinuation of Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Actual Study Start Date :

Oct 1, 2021

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

Mar 20, 2023

Outcome Measures

Primary Outcome Measures

Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery. [Files analysed retrospectively from January 01, 2000 to September 01, 2021 will be examined]]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Major subject (≥18 years old)
Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital
Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021
In whom biological confirmation of recurrence has been demonstrated
Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes.